A new independent 1878 page research with title ‘Prostate Cancer – Pipeline Review, H2 2017’ guarantees you will remain better informed than your competition. The study covers geographic analysis that includes regions and important players/vendors such as 3-V Biosciences Inc, 4SC AG, AB Science SA, AbbVie Inc, Actinium Pharmaceuticals Inc, ADC Therapeutics Sarl, Addex Therapeutics Ltd, Aduro BioTech Inc, etc…. With n-number of tables and figures examining the Prostate Cancer, the research gives you a visual, one-stop breakdown of the leading products, submarkets and market leader’s market revenue forecasts as well as analysis to 2022
Request a sample report @ https://www.htfmarketreport.com/sample-report/852551-prostate-cancer-pipeline-review-1
Prostate Cancer – Pipeline Review, H2 2017
The latest Pharmaceutical and Healthcare disease pipeline guide Prostate Cancer – Pipeline Review, H2 2017, provides an overview of the Prostate Cancer (Oncology) pipeline landscape.
Prostate cancer is a form of cancer that affects men and starts off in the prostate gland. Prostate cancer usually occurs in older men. Symptoms include trouble urinating, decreased force in the stream of urine, blood in the urine, pain in the lower back, hips or thighs, bone pain and erectile dysfunction. Predisposing factors include age, family history and obesity. Treatment includes surgery, chemotherapy and radiation therapy.
The Pharmaceutical and Healthcare latest pipeline guide Prostate Cancer – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Prostate Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Prostate Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Prostate Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 15, 99, 108, 5, 251, 31 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 10, 16, 59 and 21 molecules, respectively.
Prostate Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from The proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
– The pipeline guide provides a snapshot of the global therapeutic landscape of Prostate Cancer (Oncology).
– The pipeline guide reviews pipeline therapeutics for Prostate Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Prostate Cancer (Oncology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Prostate Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Prostate Cancer (Oncology)
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Prostate Cancer (Oncology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Prostate Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned in the Report
3-V Biosciences Inc, 4SC AG, AB Science SA, AbbVie Inc, Actinium Pharmaceuticals Inc, ADC Therapeutics Sarl, Addex Therapeutics Ltd, Aduro BioTech Inc, Advanced Accelerator Applications SA, Advanced Cancer Therapeutics LLC, Advantagene Inc, Advaxis Inc, Aeglea BioTherapeutics Inc, Aeolus Pharmaceuticals Inc, Aeterna Zentaris Inc, Akshaya Bio Inc, Alissa Pharma, Almac Discovery Ltd, ALRISE Biosystems GmbH, Ambrx Inc, Amgen Inc, Anavex Life Sciences Corp, AndroScience Corp, AnGes MG Inc, AntiCancer Inc, Antigen Express Inc, Apcure SAS, Aphios Corp, APIM Therapeutics AS, Aptevo Therapeutics Inc, Aptose Biosciences Inc, ARMO Biosciences Inc, Armour Therapeutics Inc, Arno Therapeutics Inc, ArQule Inc, Arrien Pharmaceuticals LLC, Arrowhead Pharmaceuticals Inc, Arvinas Inc, Asana BioSciences LLC, Asieris Pharmaceuticals Co Ltd, AstraZeneca Plc, Athenex Inc, Aurigene Discovery Technologies Ltd, Bavarian Nordic A/S, Bayer AG, BeiGene Ltd, Bexion Pharmaceuticals LLC, Bio-Cancer Treatment International Ltd, Biscayne Pharmaceuticals Inc, Blirt SA, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Co, Bukwang Pharm Co Ltd, Camurus AB, Can-Fite BioPharma Ltd, CanBas Co Ltd, Cantex Pharmaceuticals Inc, CEL-SCI Corp, Celgene Corp, CellCentric Ltd, Celldex Therapeutics Inc, Cellectar Biosciences Inc, Cellmid Ltd, Cellular Biomedicine Group Inc, Celprogen Inc, Clovis Oncology Inc, CohBar Inc, Colby Pharmaceutical Co, Corcept Therapeutics Inc, Corvus Pharmaceuticals Inc, Crescendo Biologics Ltd, Curadis GmbH, CytomX Therapeutics Inc, Cytori Therapeutics Inc, CytoVac AS, CZ BioMed Corp, Daewoong Co Ltd, Daewoong Pharmaceutical Co Ltd, Deciphera Pharmaceuticals LLC, DEKK-TEC Inc, DexTech Medical AB, Diffusion Pharmaceuticals Inc, DNJ Pharma Inc, Eisai Co Ltd, Eli Lilly and Co, Enceladus Pharmaceuticals BV, EndoCeutics Inc, Endocyte Inc, EntreChem SL, EOS Biosciences Inc, Errant Gene Therapeutics LLC, Esperance Pharmaceuticals Inc, ESSA Pharma Inc, Eureka Therapeutics Inc, Evgen Pharma Plc, Exonate Ltd, F. Hoffmann-La Roche Ltd, Felicitex Therapeutics Inc, Ferring International Center SA, Fountain Biopharma Inc, Fujifilm Holdings Corporation, G1 Therapeutics Inc, Galectin Therapeutics Inc, Genelux Corp, Genentech Inc, GeneSegues Inc, Genmab A/S, Gilead Sciences Inc, Glactone Pharma AB, GlaxoSmithKline Plc, GlycoMimetics Inc, GP Pharm SA, GTx Inc, Hanmi Pharmaceuticals Co Ltd, Health Ever Bio-Tech Co Ltd, Heidelberg Pharma AG, HitGen LTD, Humanigen Inc, Hybrigenics SA, IC-MedTech Inc, Ideaya Biosciences Inc, IGF Oncology LLC, Ignyta Inc, Ildong Pharmaceutical Co Ltd, Immune Pharmaceuticals Inc, Immuneed AB, Immunocore Ltd, ImmunoFrontier Inc, Immunomedics Inc, IMPACT Therapeutics Inc, Incanthera Ltd, Inflection Biosciences Ltd, InKemia IUCT Group SA, Innovation Pharmaceuticals Inc, Inovio Pharmaceuticals Inc, Inspyr Therapeutics Inc, Intech Biopharm Ltd, Io Therapeutics Inc, Ionis Pharmaceuticals Inc, Jiangsu Hengrui Medicine Co Ltd, Johnson & Johnson, Jyant Technologies Inc, Karyopharm Therapeutics Inc, Kite Pharma Inc, Komipharm International Co Ltd, Konruns Pharmaceutical Co Ltd, Kringle Pharma Inc, Kura Oncology Inc, Kyowa Hakko Kirin Co Ltd, LATITUDE Pharmaceuticals Inc, Lidds AB, Luye Pharma Group Ltd, MacroGenics Inc, Madrigal Pharmaceuticals Inc., MallInckrodt Plc, Mateon Therapeutics Inc, MaxiVAX SA, Med Discovery SA, MediaPharma SRL, MediGene AG, MedImmune LLC, Mediolanum farmaceutici SpA, Merck & Co Inc, Merck KGaA, Merrimack Pharmaceuticals Inc, Microlin Bio Inc, Millennium Pharmaceuticals Inc, Minerva Biotechnologies Corp, Mirati Therapeutics Inc, Mithra Pharmaceuticals SA, Molecular Templates Inc, MolMed SpA, Monopar Therapeutics LLC, Morphotek Inc, MTG Biotherapeutics Inc, NewLink Genetics Corp, NormOxys Inc, Novartis AG, Novus Therapeutics Inc, Noxopharm Ltd, Nymox Pharmaceutical Corp, Omeros Corp, Omnitura Therapeutics Inc, OncBioMune Pharmaceuticals Inc, Oncodrone BV, OncoMax, OncoNOx ApS, OncoTartis Inc, OncoTherapy Science Inc, Oncovir Inc, Oncternal Therapeutics Inc, Oneness Biotech Co Ltd, Ono Pharmaceutical Co Ltd, ORCA Therapeutics BV, Oric Pharmaceuticals Inc, Orion Corporation, Panacea Pharmaceuticals Inc, Patrys Ltd, PDS Biotechnology Corp, Peptron Inc, PepVax Inc, Pfizer Inc, Pharmedartis GmbH, Pharmicell Co Ltd, Philogen SpA, Polaris Pharmaceuticals Inc, Polyplus-Transfection SA, Progenics Pharmaceuticals Inc, Provectus Biopharmaceuticals Inc, Provenance Biopharmaceuticals Corp, PSites Pharma GmbH, Radiomedix Inc, RaQualia Pharma Inc, RedHill Biopharma Ltd, Regeneron Pharmaceuticals Inc, Regulaxis SAS, RhoVac AB, Rubicon Biotechnology Inc, Sanofi, Selexel Sarl, Senhwa Biosciences Inc, Serometrix LLC, Shenogen Pharma Group Ltd, Siamab Therapeutics Inc, Sierra Oncology Inc, Silenseed Ltd, Sophiris Bio Inc, Soricimed Biopharma Inc, Sorrento Therapeutics Inc, Sotio AS, SynDevRx Inc, SyntheX Inc, TaiGen Biotechnology Co Ltd, Taiho Pharmaceutical Co Ltd, Taiwan Liposome Company Ltd, Takeda Pharmaceutical Co Ltd, Takis Srl, Targovax ASA, Terpenoid Therapeutics Inc, Tesaro Inc, Teva Pharmaceutical Industries Ltd, The Female Health Company, Theravectys SA, Tolero Pharmaceuticals Inc, TRACON Pharmaceuticals Inc, TREAT U SA, Triphase Accelerator Corp, Trovagene Inc, TVAX Biomedical Inc, Tyme Technologies Inc, UbiVac LLC, Ultimovacs AS, Vaccibody AS, ValiRx Plc, Vasgen Ltd, Vault Pharma Inc, Vaxeal Holding SA, Vaxon Biotech, Vicore Pharma AB, Vicus Therapeutics LLC, Viralytics Ltd, ViraTherapeutics GmbH, VLP Therapeutics LLC, WntResearch AB, Xencor Inc, Yungjin Pharm Co Ltd, Zenith Epigenetics Ltd, Zhejiang Conba Pharmaceutical Co Ltd, Zhejiang Hisun Pharmaceutical Co Ltd
Get customization & check discount for report @ https://www.htfmarketreport.com/request-discount/852551-prostate-cancer-pipeline-review-1
Table of Contents
Prostate Cancer – Overview 13
Prostate Cancer – Therapeutics Development 14
Prostate Cancer – Therapeutics Assessment 77
Prostate Cancer – Companies Involved in Therapeutics Development 111
Prostate Cancer – Drug Profiles 233
Prostate Cancer – Dormant Projects 1763
Prostate Cancer – Discontinued Products 1797
Prostate Cancer – Product Development Milestones 1805
Appendix 1818List of Tables
Number of Products under Development for Prostate Cancer, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..6), H2 20
View Detailed Table of Content @ https://www.htfmarketreport.com/reports/852551-prostate-cancer-pipeline-review-1
Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.
Buy this report @ https://www.htfmarketreport.com/buy-now?format=1&report=852551
CRAIG FRANCIS (PR & Marketing Manager)
Ph: +1 (206) 317 1218